I currently take medication for acromegaly
If you currently take medication for acromegaly but you're interested in trying another medication, talk to your healthcare professional.
Perhaps your medication isn't working as well as you would have hoped. Maybe you're looking for a medication that's easier to administer and take. Or, possibly you're just looking for a treatment that's more convenient.
An easy-to-take, convenient alternative to other treatments: Somatuline®Depot (lanreotide) Injection (lanreotide) Injection
Ask your healthcare professional about Somatuline® Depot (lanreotide) Injection. It's FDA-approved as an effective, safe, and generally well-tolerated medical treatment for acromegaly. And it's different from other treatments.
Somatuline® Depot (lanreotide) Injection comes in a single, ready-to-use, prefilled syringe that is injected in a simple, easy procedure.
Indication and Important Safety Information
Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline Depot may experience hypoglycemia or hyperglycemia. Glucose level monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.
Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline Depot 60 mg.
There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus.
A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.
Somatuline Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.
Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline Depot may reduce the intestinal absorption of coadministered drugs. Caution should be used.
The most common adverse reactions (incidence >5%) are diarrhea (37%), cholelithiasis (20%), abdominal pain (19%), nausea (11%), injection-site reaction (9%), flatulence (7%), arthralgia (7%), and loose stools (6%).
For Full Prescribing Information, click here.
View our